UNCOOKED ALERT: Viking Therapeutics Inc said to ... - Part 3
Tuesday, 27 February 2024, 4:21 pm
Eli Lilly and Company's pursuit of Viking Therapeutics, the US-listed biopharmaceutical company developing obesity drugs, may have stalled.
People following the situation had heard speculation Eli Lilly had been trying to buy Viking for between $40 and $50 a share with a view to announcing a deal last week.
However, Viking decided the indicative price wasn't good enough and opted to announce its drug data, said people following the situation...